Skip to content

OnKure Therapeutics, Inc. OKUR Reverse Recapitalization Transaction Costs Included In Accounts Payable

Reverse Recapitalization Transaction Costs Included In Accounts Payable at other companies

PVL
Palvella TherapeuticsPVLA
$0-100%
TuHURA Biosciences, Inc. logo
TuHURA Biosciences, Inc.HURA
$550K+176%
Corvex
 logo
Corvex MOVE
$37.5K
DTC
Datacentrex, Inc. DTCX
-$31.9K
DTC
Datacentrex, Inc. DTCX
$10.54M
TuHURA Biosciences, Inc. logo
TuHURA Biosciences, Inc.HURA
$137.5K

Other financials

Income statement

See full
Revenue-
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$184.2M+72.6%
Enterprise value-$7.49M-127%

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.0×
Current ratio13.8×+2.6×

Where this comes from

Reported directly by OnKure Therapeutics, Inc. in its filing.

Tagged under the XBRL concept okur:ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable.

The official record: OnKure Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s reverse recapitalization transaction costs included in accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s reverse recapitalization transaction costs included in accounts payable?
OnKure Therapeutics, Inc. (OKUR) reported reverse recapitalization transaction costs included in accounts payable of $10K in Q4 2024.
What does reverse recapitalization transaction costs included in accounts payable mean?
Accrued expenses related to reverse recapitalization activities that have been recorded in accounts payable but not yet settled with cash. This represents a short-term liability incurred to support the corporate restructuring process.